Biomarker for Hurler Disease (BioHurler)
NCT02298712 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2023-02-13
Summary
Development of a new MS-based biomarker for the early and sensitive diagnosis of Hurler disease from plasma. Testing for clinical robustness, specificity and long-term stability of the biomarker.
Conditions
- Mucopolysaccharidosis Type I
- Gargoylism
- Metabolism, Inborn Errors
Sponsors & Collaborators
-
CENTOGENE GmbH Rostock
lead INDUSTRY
Principal Investigators
-
Peter Bauer, Prof. · Centogene GmbH
Eligibility
- Min Age
- 2 Months
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-20
- Primary Completion
- 2021-02-28
- Completion
- 2021-02-28
Countries
- Egypt
- Germany
- India
- Sri Lanka
Study Locations
More Related Trials
-
A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy
NCT00936546 ·Status: COMPLETED ·Phase: PHASE2
-
A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome
NCT02422407 ·Status: COMPLETED
-
Personalized Therapy of Patients Suffering From Rare Genodermatoses
NCT05680974 ·Status: UNKNOWN
-
Stem Cell Factor, a Potential Biological Marker of Skin Involvement in Systemic Sclerosis?
NCT05482594 ·Status: UNKNOWN
-
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
NCT02471352 ·Status: RECRUITING
-
Treatment of Early Systemic Sclerosis by Bosentan
NCT00226889 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Epidermal Growth Factor Receptor Inhibition for Keratinopathies
NCT06545695 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Systemic Sclerosis Clinical and Biomarker Study
NCT02531009 ·Status: WITHDRAWN
-
A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa
NCT04599881 ·Status: COMPLETED ·Phase: PHASE2
-
Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T
NCT02332902 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Biomarkers in Susac Syndrome
NCT01273792 ·Status: UNKNOWN
-
Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
NCT00433485 ·Status: COMPLETED ·Phase: PHASE1
-
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT06599411 ·Status: NOT_YET_RECRUITING
-
Study of Scaling Disorders and Other Inherited Skin Diseases
NCT00001292 ·Status: COMPLETED
-
Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers
NCT01971957 ·Status: COMPLETED
-
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
NCT02370693 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
NCT01538862 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
NCT02465437 ·Status: TERMINATED ·Phase: PHASE2
-
Examining the Immunological Process of Autoimmune Patients
NCT02123147 ·Status: WITHDRAWN
-
Genetic Variants in Linear Localized Scleroderma
NCT02222038 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
NCT00043706 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
NCT05488327 ·Status: UNKNOWN ·Phase: NA
-
Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1
NCT02680431 ·Status: UNKNOWN
-
Defining the Skin and Blood Biomarkers of Ichthyosis
NCT03417856 ·Status: ENROLLING_BY_INVITATION
-
Genotype-phenotype Correlation in Junctional Epidermolysis Bullosa
NCT04727268 ·Status: UNKNOWN